XenoPort, Inc. Presents New Analyses Of Data For Gabapentin Enacarbil At The 33rd Annual Scientific Meeting Of The American Pain Society

Published: Apr 30, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

XenoPort, Inc. (Nasdaq: XNPT) announced today that it will present new analyses of data for gabapentin enacarbil (GEn), the active ingredient in HORIZANT® (gabapentin enacarbil) Extended-Release Tablets, at the 33rd Annual Scientific Meeting of the American Pain Society (APS) in Tampa, Florida.

Help employers find you! Check out all the jobs and post your resume.

Back to news